Abstracts tagged "Disease Activity"

Abstract Number: 2820 • 2017 ACR/ARHP Annual Meeting
Disease Activity By the Sledai in Lupus Patients Who Self Report Sleep Disturbance and Sleep Impairment Using the Patient-Reported Outcomes Measurement Information System Instruments
Teresa Aberle¹, Rufei Lu², Sarah Cioli³, Stan Kamp¹, Wade DeJager¹, Stephen Apel⁴, Cristina Arriens⁵, Eliza Chakravarty⁶, Aikaterini Thanou¹, Joel M. Guthridge⁷, Joan T. Merrill⁸ and Judith A. James⁹, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Oklahoma Medical research af, Edmond, OK, ⁷Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK, ⁸Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Lupus patients commonly report sleep dysfunction, which is associated with upregulation of inflammatory cytokines in healthy people. Studies exploring relationships between self-reported sleep dysfunction…
Abstract Number: 435 • 2017 ACR/ARHP Annual Meeting
Characteristics of Rheumatoid Arthritis Patients Who Have a DMARD Interruption and the Impact of Using a Bridging Medication on Clinical and Patient Reported Outcomes
Christine Iannaccone¹, Michelle Frits², Taysir G. Mahmoud³, Gabriela Maica⁴, Jonathan Coblyn⁵, Michael Weinblatt² and Nancy A. Shadick⁶, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Department of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, MA, ⁵Department of Rheumatology, Brigham & Womens Hospital, Boston, MA, ⁶Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: It is common for RA patients to interrupt their DMARD use due to events like infection, surgery, or pregnancy. Many RA patients may need…
Abstract Number: 921 • 2017 ACR/ARHP Annual Meeting
Discordant Patient-Physician Assessments of Disease Activity and Its Persistence Adversely Impact Quality of Life and Work Productivity in United States Hispanics with Rheumatoid Arthritis
George Karpouzas¹, Sera Ramadan², Chelsie Cost³, Taylor Draper⁴, Elizabeth Hernandez³ and Sarah Ormseth³, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Internal Medicine, Dignity Health St. Mary Medical Center, Long Beach, CA, ³Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁴Psychology, Loma Linda University, Loma Linda, CA
Background/Purpose: The impact of discordant patient-physician assessments of rheumatoid arthritis (RA) activity on quality of life is largely unknown. We examined the prevalence and stability…
Abstract Number: 1358 • 2017 ACR/ARHP Annual Meeting
Relationship between Serum Protein Pattern and High Disease Activity in Patients with Rheumatoid Arthritis
Pavel Horak¹, Anna Petráčková², Martina Skácelová³, Eva Kriegová⁴, Petra Schneiderová⁵ and František Mrázek⁵, ¹III. Department of internal medicine, III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic, ²Department of Immunology, Department of Immunology, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic, ³III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic, ⁴Department of Immunology,, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic, ⁵Department of Immunology, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects joints. There is still limited information of serum biomarkers suitable for effective monitoring…
Abstract Number: 1624 • 2017 ACR/ARHP Annual Meeting
SLE Disease Activity Index Glucocorticosteroid Index (SLEDAI-2KG) Identifies More Responders Than Sledai-2K
Zahi Touma¹, Dafna D Gladman², Jiandong Su³, Nicole Anderson⁴ and Murray Urowitz⁴, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) is one of the most commonly used disease activity indices in clinical practice and research but this…
Abstract Number: 1992 • 2017 ACR/ARHP Annual Meeting
Changes in Clinical Disease Activity Are Associated with Changes in the Total MRI Inflammation Score in Rheumatoid Arthritis Patients Who Are Escalating Therapy in a Treat-to-Target (T2T) Regimen
Fiona M. McQueen¹, Peter T. Chapman², Terina Pollock³, Dena D'Souza⁴, Arier Lee⁵, Nicola Dalbeth⁶, Lisa K. Stamp⁷, Karen Lindsay⁸ and Anthony Doyle^3,9, ¹Molecular Medicine, Univ of Auckland Sch of Med, Auckland, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Radiology, Auckland District Health Board, Auckland, New Zealand, ⁴Rheumatology, University of Auckland, Auckland, New Zealand, ⁵Biostatistics and Epidemiology, University of Auckland, Auckland, New Zealand, ⁶University of Auckland, Auckland, New Zealand, ⁷University of Otago, Christchurch, New Zealand, ⁸Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁹Anatomy with Radiology, University of Auckland, Auckland, New Zealand
Background/Purpose: RA patients are managed using treat-to target (T2T) regimens often utilizing the DAS28CRP as an outcome measure. In this study we compared clinical changes…
Abstract Number: 2485 • 2017 ACR/ARHP Annual Meeting
Outcomes of Switching from TNF Inhibitors to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
Hiroki Wakabayashi¹, Hitoshi Inada², Yosuke Nishioka³, Masahiro Hasegawa^1,4, Kusuki Nishioka⁵ and Akihiro Sudo⁶, ¹Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, ²Orthopaedic Surgery, Suzuka General Hospital, Suzuka, Japan, ³Clinical Research Institute for Rheumatic Disease, Shima, Japan, ⁴Mie University Graduate School of Medicine, Tsu, Japan, ⁵Tokyo Medical University, Shinjuku, Japan, ⁶Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan
Background/Purpose: Tumor necrosis factor alpha (TNFα) inhibitors have been used to treat rheumatoid arthritis (RA) for >10 years. The outcomes has revolutionized the treatment goal…
Abstract Number: 2834 • 2017 ACR/ARHP Annual Meeting
Healthcare Cost Drivers in Rheumatoid Arthritis
Nina Mars¹, Anne M Kerola^2,3, Markku J Kauppi^4,5, Matti Pirinen¹, Outi Elonheimo⁶ and Tuulikki Sokka-Isler⁷, ¹Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, ²Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ³University of Helsinki, Helsinki, Finland, ⁴School of Medicine, University of Tampere, Tampere, Finland, ⁵Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁶FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Rheumatoid arthritis (RA) is associated with high healthcare resource utilization, but knowledge about factors determining healthcare costs is limited. The aim was to identify…
Abstract Number: 63 • 2017 Pediatric Rheumatology Symposium
Performance of Disease Activity Measures in Pediatric Patients With Enthesitis-related Arthritis
Rubén Burgos-Vargas¹, Gerd Horneff², Shirley M.L. Tse³, Pierre Quartier⁴, Kristina Unnebrink⁵ and Jaclyn K. Anderson⁶, ¹Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ²Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose: Enthesitis-related arthritis (ERA) is a category of juvenile idiopathic arthritis (JIA), with clinical features similar to those of adult spondyloarthritis (SpA). An unmet ERA…
Abstract Number: 101 • 2017 Pediatric Rheumatology Symposium
Defining Active Features of Juvenile Localized Scleroderma
Suzanne Li¹, Xiaohu Li², Elena Pope³, Katie G. Stewart⁴, Gloria Higgins⁵, C. Egla Rabinovich⁶, Kathleen O'Neil⁷, Kathleen Haines⁸, Ronald Laxer⁹, Marilynn Punaro¹⁰, Heidi Jacobe¹¹, Knut Wittkowski¹², Themba Nyirenda¹³, Ivan Foeldvari¹⁴ and Kathryn S. Torok¹⁵, ¹Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ²Mathematical Sciences, Stevens Institute of Technology, Hoboken, NJ, ³Dermatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ⁵Pediatrics, Nationwide Children's Hospital, Columbus, OH, ⁶Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ⁷Pediatrics, Indiana University, Indianapolis, IN, ⁸Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ⁹Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Texas Scottish Rite Hospital for Children, Dallas, TX, ¹¹Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ¹²Rockefeller University, New York, NY, ¹³Hackensack University Medical Center, Hackensack, NJ, ¹⁴Kinder- und Jugenrheumatologie, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, ¹⁵Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA
Background/Purpose: Juvenile localized scleroderma (jLS) is the most common form of childhood scleroderma. Because of its chronicity and association with extracutaneous involvement, children are at…
Abstract Number: 5 • 2017 Pediatric Rheumatology Symposium
Effects of Puberty on Systemic Lupus Erythematosus: Results of a multi-center prospective longitudinal observational study in children entering puberty with SLE
Kathleen O'Neil¹, Hermine Brunner², Andrew Zeft³, Anne Stevens⁴, Suzanne Li⁵, Tracey Wright⁶, Emily von Scheven⁷, B. Anne Eberhard⁸, C. Egla Rabinovich⁹ and Deborah M. Levy¹⁰, ¹Pediatrics, Indiana University, Indianapolis, IN, ²Rheumatology, PRCSG, Cincinnati, OH, ³Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ⁴University of Washington, Department of Pediatrics, Seattle, WA, ⁵Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ⁶Pediatrics/Rheumatology, University of TX Southwestern, Dallas, TX, ⁷Division of Rheumatology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, ⁸Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁹Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ¹⁰Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Lupus often presents during puberty, and when it affects pre-pubertal children, disease activity is thought to increase at puberty. Sex hormones play some role…
Abstract Number: 272 • 2016 ACR/ARHP Annual Meeting
Interferon Chemokine Score and Other Cytokine Measures Predict Changes in Disease Activity in Patients with Juvenile and Adult Dermatomyositis
Cynthia S. Crowson¹, Jeannette M. Olazagasti Lourido², Molly S. Hein³, Richard S. Pendegraft⁴, Michael A. Strausbauch⁵, Timothy B. Niewold⁶, Floranne C. Ernste⁷, Theresa L. Wampler Muskardin³, Erik J. Peterson⁸, Emily C. Gillespie⁹ and Ann M Reed¹⁰, ¹Health Sciences Research, Mayo Clinic, Rochester, MN, ²University of Puerto Rico, San Juan, Puerto Rico, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Biomedical Statistics and informatics, Rochester, MN, ⁵Surgical Research, Mayo Clinic, Rochester, MN, ⁶Rheumatology and Immunology, Mayo Clinic, Rochester, MN, ⁷Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁸Center for Immunology/Department of Medicine, University of Minnesota, Minneapolis, MN, ⁹Medicine, University of Minnesota, Minneapolis, MN, ¹⁰Rheumatology, Duke University, Durham, NC
Background/Purpose: Methods: Multiplexed immunoassays (Meso Scale Discovery) enabled simultaneous measurement of IFN-regulated chemokines and other pro- and anti-inflammatory cytokines specific to differentiation of specific…
Abstract Number: 556 • 2016 ACR/ARHP Annual Meeting
Higher Multi Biomarker Disease Activity Scores Foreshadow Greater Longitudinal Improvement in RA Disease Activity
Jeffrey Curtis¹, Leslie Harrold², Joel Kremer³ and J. Lynn Palmer⁴, ¹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²U Massachusetts, Worcester, MA, ³Albany Medical Center, Albany, NY, ⁴Corrona Research Foundation, Albany, NY
Background/Purpose: Biomarkers in patients with rheumatoid arthritis (RA) have the attractive potential to help select patients that have a greater burden of disease activity and…
Abstract Number: 902 • 2016 ACR/ARHP Annual Meeting
High Disease Activity Scores and Leptin Levels in Takayasu Patients with Overweight and Obesity
Gokce Kenar¹, Handan Yarkan², Berrin Zengin¹, Gerçek Can², Merih Birlik¹, Nurullah Akkoc¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ²Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey
Background/Purpose: We aimed to determine the prevalence of overweight, obesity and metabolic syndrome (MetS) and leptin levels in patients with Takayasu arteritis (TA) and their…
Abstract Number: 1375 • 2016 ACR/ARHP Annual Meeting
A Five Year Study of 102 Children with Juvenile Myositis: Disease Course and Outcomes
Lauren M. Pachman^1,2,3, Megan L. Curran⁴, Gabrielle A. Morgan^5,6, Maria C. Amoruso^1,7, Ira N. Targoff^8,9 and Chiang-Ching Huang¹⁰, ¹Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ²Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Rheumatology/Immunology, Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, IL, ⁴Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Cure JM Program of Excellence in Myositis Research, Chicago, IL, ⁶Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁷Immunology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹University of Oklahoma, Oklahoma City, OK, ¹⁰Zilber School of Public Health, University of Wisconsin, Milwaukee, Milwaukee, WI
Background/Purpose: Children with juvenile myositis (JM) have a variable disease course, in part associated with myositis specific/associated antibodies (MSA). Time to off medications has not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].